News & Updates

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

In the 52-week open-label extension (OLE) of a phase IIb study presented at AAAAI 2023, the BTK* inhibitor remibrutinib demonstrated sustained efficacy and a favourable safety profile for the treatment of chronic spontaneous urticaria (CSU).

Treatment with phosphodiesterase 5 inhibitors (PDE5i) may provide survival benefits to patients with interstitial lung disease (ILD)-related pulmonary hypertension (PH), particularly in those with severe disease and normal baseline right ventricular (RV) dysfunction, suggest the results of a retrospective observational cohort study.

A recent study has provided further evidence on the incidence of central nervous system (CNS) coccidioidomycosis, which is a rare and potentially dangerous complication of disseminated coccidioidomycosis. Many patients present with relatively low compliment fixation (CF) titer, and hydrocephalus often occurs.